Drug Trial Radar · NCT06387420
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Apr 29, 2024
Primary completion
Apr 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.
Conditions
- ACUTE MYELOID LEUKEMIA; AML
Interventions
AK117Drug
Subjects receive AK117 intravenously.
AzacitidineDrug
Subjects receive azacitidine subcutaneously.
VenetoclaxDrug
Subjects receive venetoclax orally.
PlaceboOther
Subjects receive placebo intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of participants with dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Phase 1b/2: Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years.
- Phase 1b/2: Composite complete remission rate (CCR)Time frame: Time Frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.